

KAYNAKLAR

1. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. *Drug safety*. 2001;24(10):767-79.
2. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology*. 2009;39(12):1786-800.
3. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. *Clinical reviews in allergy & immunology*. 2003;24(3):253-62.
4. Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. *British journal of cancer*. 2013;109(3):552-8.
5. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2001;19(12):3126-9.
6. Georgoulas V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2005;23(13):2937-45.
7. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. *Oncology*. 2009;76(4):231-8.
8. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. *The oncologist*. 2007;12(5):601-9.
9. Okada N, Ishibashi K, Kuwabara K, Ishiguro T, Hatano S, Hokama N, et al. [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy]. *Gan to kagaku ryoho Cancer & chemotherapy*. 2009;36(12):1985-7.
10. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. *Current allergy and asthma reports*. 2008;8(1):56-62.
11. Georgoulas V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. *British journal of cancer*. 2005;93(7):763-9.
12. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. *Journal of hematology & oncology*. 2010;3:12.
13. Hausmann O, Schnyder B, Pichler WJ. Drug hypersensitivity reactions involving skin. *Handbook of experimental pharmacology*. 2010(196):29-55.
14. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2008;18(4):615-20.
15. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. *The journal of allergy and clinical immunology In practice*. 2013;1(5):494-500.

16. Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? *Anti-cancer drugs*. 2010;21(3):333-8.
17. Leguy-Seguín V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. *The Journal of allergy and clinical immunology*. 2007;119(3):726-30.
18. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. *The Journal of allergy and clinical immunology*. 2008;122(3):574-80.
19. Breslin S. Cytokine-release syndrome: overview and nursing implications. *Clinical journal of oncology nursing*. 2007;11(1 Suppl):37-42.
20. Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. *The Journal of allergy and clinical immunology*. 2012;129(2):443-7.
21. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. *The Journal of allergy and clinical immunology*. 2009;123(6):1262-7.e1.
22. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2009;102(2):155-60.
23. Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2004;43(3):329-33.
24. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2000;18(1):102-5.
25. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. *Journal of immunology (Baltimore, Md : 1950)*. 1999;162(11):6811-8.
26. Pinder MC, Ibrahim NK. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. *Drugs of today (Barcelona, Spain : 1998)*. 2006;42(9):599-604.
27. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2009;102(3):179-87; quiz 87-9, 222.
28. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreira-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. *Allergy*. 2013;68(7):853-61.
29. Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN. Hypersensitivity reactions to antineoplastic agents: an overview. *Anti-cancer drugs*. 2009;20(1):1-6.
30. Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, Disilvestro P, et al. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. *Gynecologic oncology*. 2006;100(1):149-51.

31. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2006;17(8):1263-8.
32. Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2009;19(7):1281-3.
33. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. *Gynecologic oncology*. 2005;96(3):824-9.
34. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. *Archives of dermatology*. 2000;136(12):1475-80.
35. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. *Gynecologic oncology*. 2005;99(2):393-9.
36. Holcenberg J. Optimal asparaginase therapy. *Journal of pediatric hematology/oncology*. 2004;26(5):273-4.
37. Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated *E. coli* and *Erwinia* asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). *Anticancer research*. 2009;29(1):299-302.
38. Shinnick SE, Browning ML, Koontz SE. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults. *Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses*. 2013;30(2):63-77.
39. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2000;18(7):1525-32.
40. Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, et al. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. *Anti-cancer drugs*. 2010;21(6):651-5.
41. Collier K, Schink C, Young AM, How K, Seckl M, Savage P. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2008;14(1):51-5.
42. Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. *British journal of cancer*. 2002;86(1):12-3.